Athenex announces sale of revenues from u.s. and european royalty and milestone interests in klisyri® (tirbanibulin) to sagard healthcare partners and oaktree

Buffalo, n.y., june 22, 2022 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the signing of a definitive agreement for the sale of revenues from u.s. and european royalty and milestone interests in klisyri® (tirbanibulin) to sagard healthcare partners and funds managed by oaktree capital management, l.p. (“oaktree”) for $85 million. approximately $80 million of the proceeds from the transaction will be used toward partially paying down existing debt and operating the business, with $5 million to be placed into escrow and paid to athenex upon the satisfaction of certain conditions. the transaction is subject to customary closing conditions.
ATNX Ratings Summary
ATNX Quant Ranking